TDMS Study 92012-06 Pathology Tables
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
FINAL #1; REVISION #2 MICE
Facility: Southern Research Institute
Chemical CAS #: 693-98-1
Lock Date: 10/16/01
Cage Range: All
Reasons For Removal: 25019 Moribund Sacrifice 25020 Natural Death
25026 Other 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Moribund Sacrifice 2 3 4 4
Natural Death 2 3 2 1
Survivors
Terminal Sacrifice 46 42 42 45
Moribund Sacrifice 1
Natural Death 1
Other 1 1
Animals Examined Microscopically 50 49 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (48) (48) (50)
Edema 2 [2.0] 2 [2.0] 2 [2.0]
Intestine Small, Jejunum (50) (46) (48) (49)
Hyperplasia, Lymphoid 1 [3.0] 1 [3.0]
Peyer's Patch, Infiltration Cellular,
Polymorphonuclear 1 [3.0]
Intestine Small, Ileum (47) (49) (47) (48)
Hyperplasia, Lymphoid 1 [3.0]
Peyer's Patch, Infiltration Cellular,
Polymorphonuclear 1 [3.0]
Liver (50) (49) (49) (50)
Angiectasis 1 [3.0]
Basophilic Focus 4 1 1
Clear Cell Focus 1 1 4
Eosinophilic Focus 1
Hematopoietic Cell Proliferation 3 [3.0] 3 [2.0] 5 [1.8] 3 [3.0]
Hemorrhage 1 [3.0]
Hepatodiaphragmatic Nodule 1 2
Hyperplasia, Lymphoid 3 [2.0] 3 [2.3] 6 [2.2]
Infarct 1 [3.0]
Infiltration Cellular, Mixed Cell 13 [1.7] 5 [1.6] 12 [1.3] 10 [1.1]
Mixed Cell Focus 4 1 3
Necrosis, Focal 5 [1.6] 2 [1.0] 3 [2.7] 4 [3.3]
Tension Lipidosis 2
Bile Duct, Hyperplasia 1 [3.0]
Hepatocyte, Vacuolization Cytoplasmic 1 [3.0]
Kupffer Cell, Pigmentation 2 [4.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Mesentery (3) (4) (6) (6)
Inflammation, Chronic 1 [4.0] 1 [3.0]
Fat, Angiectasis 1 [3.0] 1 [3.0]
Fat, Necrosis 2 [3.0] 3 [2.3] 6 [1.8] 6 [2.8]
Pancreas (50) (49) (48) (50)
Atrophy 1 [4.0]
Cyst 1 [3.0] 1 [3.0] 1 [3.0] 2 [3.0]
Acinus, Cytoplasmic Alteration 2 [3.0] 1 [3.0]
Salivary Glands (50) (49) (49) (49)
Atrophy 2 [2.0] 1 [1.0]
Hyperplasia, Lymphoid 5 [2.6] 3 [2.0] 2 [2.0]
Stomach, Forestomach (50) (49) (49) (50)
Diverticulum 1 5
Inflammation, Chronic Active 1 [2.0] 1 [2.0] 2 [2.5]
Epithelium, Hyperplasia 1 [2.0] 4 [2.5] 1 [1.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (49) (50)
Cardiomyopathy 2 [1.0]
Thrombosis 1 [3.0]
Myocardium, Necrosis 1 [2.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (49) (50)
Accessory Adrenal Cortical Nodule 7 [3.0] 5 [3.0] 4 [3.0] 6 [3.0]
Hyperplasia, Focal 2 [1.5]
Capsule, Hyperplasia 3 [2.0]
Adrenal Medulla (50) (49) (49) (50)
Hyperplasia 1 [2.0]
Islets, Pancreatic (50) (48) (48) (50)
Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0]
Parathyroid Gland (48) (46) (45) (48)
Cyst 1 [3.0] 1 [3.0] 1 [3.0]
Pituitary Gland (50) (49) (47) (49)
Pars Distalis, Angiectasis 3 [2.3] 1 [2.0] 1 [2.0]
Pars Distalis, Cyst 1 [3.0] 3 [3.0] 1 [2.0]
Pars Distalis, Hyperplasia, Focal 1 [3.0] 2 [1.5] 1 [1.0] 2 [2.0]
Thyroid Gland (49) (48) (48) (50)
Degeneration, Cystic 15 [2.1] 14 [1.8] 12 [1.7] 9 [1.2]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Follicle, Cyst 1 [3.0] 1 [3.0]
Follicular Cell, Hyperplasia 1 [1.0] 1 [2.0] 1 [1.0] 9 [1.6]
Follicular Cell, Hypertrophy 6 [1.2] 3 [1.0] 23 [1.1] 46 [1.7]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (48) (48) (50)
Inflammation, Chronic 1 [4.0]
Ovary (50) (49) (49) (48)
Angiectasis 12 [2.3] 7 [2.4] 8 [2.8] 8 [2.6]
Cyst 10 [3.0] 11 [3.0] 15 [3.0] 10 [3.0]
Inflammation, Chronic 3 [4.0] 2 [3.0]
Thrombosis 1 [4.0]
Corpus Luteum, Hyperplasia 1 [3.0]
Uterus (50) (49) (49) (50)
Angiectasis 3 [3.3] 2 [2.5] 2 [3.5] 6 [2.2]
Inflammation, Chronic 6 [2.8] 2 [2.0] 9 [2.7] 4 [3.3]
Metaplasia, Squamous 5 [3.0] 5 [3.0] 1 [3.0]
Cervix, Cyst Epithelial Inclusion 1
Endometrium, Fibrosis 1 [3.0]
Endometrium, Hyperplasia, Cystic 48 [3.0] 47 [3.1] 46 [3.3] 45 [3.4]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (48) (50)
Hyperplasia 10 [2.7] 5 [2.0] 13 [3.2] 16 [2.4]
Lymph Node (12) (6) (8) (9)
Bronchial, Hyperplasia, Lymphoid 1 [3.0] 2 [2.5]
Iliac, Ectasia 1 [3.0]
Iliac, Hematopoietic Cell Proliferation 2 [2.5] 1 [2.0] 1 [2.0]
Iliac, Hyperplasia, Lymphoid 5 [2.2] 3 [3.0] 4 [3.0] 2 [4.0]
Iliac, Pigmentation 1 [2.0]
Inguinal, Hyperplasia, Lymphoid 1 [2.0]
Lumbar, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 2 [3.0] 2 [3.0]
Lumbar, Pigmentation 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid 1 [4.0] 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Pancreatic, Hyperplasia, Lymphoid 1 [2.0]
Renal, Hematopoietic Cell Proliferation 1 [3.0] 1 [2.0]
Renal, Hyperplasia, Lymphoid 3 [2.7] 1 [4.0] 2 [2.5]
Lymph Node, Mandibular (48) (48) (46) (48)
Atrophy 2 [2.5]
Hematopoietic Cell Proliferation 3 [2.3]
Hemorrhage 1 [2.0]
Hyperplasia, Lymphoid 11 [2.0] 12 [1.8] 10 [2.0] 15 [1.7]
Hyperplasia, Plasma Cell 2 [2.0] 1 [3.0] 4 [1.8]
Pigmentation 24 [2.2] 20 [2.2] 21 [2.2] 21 [2.1]
Lymph Node, Mesenteric (48) (48) (47) (48)
Ectasia 1 [2.0]
Hematopoietic Cell Proliferation 5 [2.2] 3 [2.3] 3 [2.3]
Hemorrhage 1 [2.0] 1 [2.0]
Hyperplasia, Lymphoid 3 [2.3] 7 [2.9] 4 [2.5] 6 [2.7]
Hyperplasia, Plasma Cell 1 [3.0]
Spleen (50) (49) (49) (50)
Angiectasis 1 [2.0]
Atrophy 1 [1.0] 1 [2.0]
Congestion 2 [2.0]
Hematopoietic Cell Proliferation 15 [2.1] 20 [2.2] 24 [2.5] 39 [2.4]
Hyperplasia, Plasma Cell 1 [3.0]
Pigmentation 4 [1.3] 11 [1.5] 34 [1.7]
Lymphoid Follicle, Atrophy 1 [2.0] 3 [2.0] 5 [2.6] 4 [3.3]
Lymphoid Follicle, Hyperplasia 12 [1.8] 14 [1.8] 13 [2.3] 16 [2.2]
Thymus (50) (48) (48) (50)
Atrophy 5 [2.6] 2 [2.0] 7 [3.1] 3 [3.0]
Hyperplasia, Lymphoid 4 [2.5]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Hyperplasia 2 [2.5] 2 [1.0]
Skin (50) (49) (49) (50)
Edema 1 [3.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (49) (50)
Hyperostosis 9 [1.9] 13 [2.2] 10 [2.2] 11 [2.1]
Skeletal Muscle (1) (1)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - CONT
Necrosis 1 [4.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (49) (50)
Hemorrhage 1 [1.0] 1 [2.0]
Inflammation, Chronic Active 1 [2.0]
Vacuolization Cytoplasmic 1 [3.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (49) (50)
Edema 2 [2.0] 1 [2.0]
Foreign Body 2 2 2
Hemorrhage 4 [1.3] 3 [1.3] 1 [2.0] 4 [1.5]
Hyperplasia, Lymphoid 9 [2.2] 6 [2.0] 3 [2.0] 7 [2.3]
Infiltration Cellular, Histiocyte 2 [1.5] 2 [2.5] 3 [2.7]
Thrombosis 1 [2.0] 1 [1.0]
Alveolar Epithelium, Hyperplasia 1 [1.0] 2 [2.0] 3 [2.0] 2 [2.0]
Nose (50) (49) (49) (50)
Foreign Body 1
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (49) (49) (50)
Atrophy 1 [4.0]
Cataract 1 [2.0] 2 [2.5]
Inflammation, Chronic 1 [1.0] 2 [2.5]
Harderian Gland (50) (49) (49) (50)
Hyperplasia 1 [2.0]
Hyperplasia, Focal 3 [3.0] 2 [2.0] 1 [2.0]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (50)
Cyst 1 [3.0] 2 [3.0] 1 [3.0] 1 [3.0]
Hyperplasia, Lymphoid 8 [2.0] 16 [2.1] 8 [2.1] 4 [2.3]
Infarct 2 [1.5] 2 [3.0]
Inflammation, Chronic 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Metaplasia, Osseous 1 [2.0] 2 [2.5]
Nephropathy 27 [1.1] 17 [1.1] 21 [1.1] 19 [1.0]
Papilla, Necrosis 1 [3.0]
Renal Tubule, Accumulation, Hyaline Droplet 1 [2.0] 1 [4.0]
Renal Tubule, Dilatation 1 [2.0]
Renal Tubule, Necrosis 1 [3.0] 1 [2.0]
Renal Tubule, Pigmentation 2 [2.5]
Urinary Bladder (50) (49) (49) (50)
Hyperplasia, Lymphoid 16 [2.3] 16 [2.1] 6 [2.0] 11 [2.3]
Inflammation, Chronic 1 [1.0] 1 [2.0]
Transitional Epithelium, Hyperplasia 1 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Moribund Sacrifice 4 1 5 5
Natural Death 3 3 9 5
Survivors
Terminal Sacrifice 43 46 36 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (49) (49) (47) (50)
Edema 2 [2.0] 1 [2.0] 1 [2.0] 1 [2.0]
Intestine Small, Duodenum (49) (49) (45) (50)
Epithelium, Hyperplasia 1 [3.0]
Intestine Small, Jejunum (50) (49) (46) (50)
Hyperplasia, Lymphoid 1 [2.0] 1 [3.0]
Infiltration Cellular, Polymorphonuclear 1 [3.0]
Intestine Small, Ileum (49) (50) (45) (49)
Hyperplasia, Lymphoid 1 [2.0] 1 [2.0]
Infiltration Cellular, Polymorphonuclear 1 [2.0]
Liver (50) (50) (50) (50)
Angiectasis 2 [3.0] 1 [4.0]
Basophilic Focus 2 3 1 3
Clear Cell Focus 6 9 6 8
Cyst 1 [3.0]
Eosinophilic Focus 3 3 2 6
Hematopoietic Cell Proliferation 1 [3.0] 2 [1.5] 2 [2.0]
Hepatodiaphragmatic Nodule 1
Infarct 1
Infiltration Cellular, Mixed Cell 5 [1.4] 7 [1.1] 7 [1.3] 7 [1.4]
Mixed Cell Focus 4 3 4 4
Necrosis, Diffuse 1 [3.0]
Necrosis, Focal 2 [2.0] 6 [1.5] 2 [2.5] 6 [2.2]
Tension Lipidosis 2 1
Hepatocyte, Cytoplasmic Alteration 11 [1.2] 37 [1.8]
Hepatocyte, Karyomegaly 10 [1.0] 29 [1.3]
Hepatocyte, Vacuolization Cytoplasmic 1 [3.0] 1 [2.0]
Kupffer Cell, Pigmentation 1 [3.0] 1 [2.0] 19 [1.5]
Mesentery (6) (2) (5) (2)
Angiectasis 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation, Chronic 1 [1.0]
Fat, Necrosis 4 [2.3] 1 [2.0] 3 [2.3] 2 [2.5]
Pancreas (50) (50) (49) (50)
Atrophy 1 [2.0] 1 [4.0]
Cyst 2 [3.0] 3 [3.0] 2 [3.0]
Acinus, Cytoplasmic Alteration 2 [2.0] 1 [3.0]
Salivary Glands (50) (50) (50) (50)
Hyperplasia, Lymphoid 2 [2.0] 2 [2.0]
Stomach, Forestomach (50) (49) (50) (50)
Diverticulum 2
Inflammation, Chronic Active 1 [2.0] 1 [1.0]
Ulcer 1 [3.0] 1 [3.0]
Epithelium, Hyperplasia 2 [2.0] 2 [1.5] 1 [2.0] 1 [3.0]
Stomach, Glandular (50) (49) (49) (50)
Glands, Dysplasia 1 [3.0]
Tooth (1)
Inflammation, Chronic 1 [4.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 1 [1.0] 1 [1.0]
Perivascular, Inflammation, Chronic 3 [1.7]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Accessory Adrenal Cortical Nodule 2 [3.0] 6 [3.0] 8 [3.0] 6 [3.0]
Hyperplasia, Focal 2 [1.5] 4 [1.5] 3 [1.3] 1 [1.0]
Hypertrophy, Focal 13 [1.3] 18 [1.6] 10 [1.2] 10 [1.7]
Capsule, Hyperplasia 1 [1.0] 2 [1.5] 3 [1.3] 2 [1.5]
Adrenal Medulla (50) (50) (50) (50)
Hyperplasia 2 [1.5]
Islets, Pancreatic (50) (50) (49) (50)
Hyperplasia 2 [2.0] 1 [2.0]
Parathyroid Gland (49) (47) (45) (48)
Cyst 3 [3.0] 1 [3.0] 2 [3.0] 1 [3.0]
Pituitary Gland (49) (48) (48) (50)
Pars Distalis, Cyst 2 [3.0] 1 [3.0] 2 [3.0] 2 [3.0]
Pars Distalis, Hyperplasia, Focal 1 [4.0]
Thyroid Gland (50) (50) (50) (50)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Degeneration, Cystic 10 [2.0] 2 [1.0] 3 [2.0] 4 [1.5]
Follicular Cell, Hyperplasia 2 [1.5] 3 [1.7] 33 [1.9]
Follicular Cell, Hypertrophy 1 [1.0] 6 [1.2] 25 [1.3]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Fibrosis 1 [2.0]
Granuloma Sperm 3 [2.7] 6 [2.5]
Hyperplasia, Lymphoid 2 [2.5] 1 [3.0]
Hypospermia 1 [4.0]
Inflammation, Chronic Active 1 [1.0] 3 [1.3] 7 [2.0] 8 [2.9]
Penis (1) (1) (1)
Angiectasis 1 [3.0] 1 [3.0]
Preputial Gland (50) (50) (50) (50)
Cyst 18 [3.0] 23 [3.0] 16 [3.0] 21 [3.0]
Inflammation, Chronic 14 [2.4] 10 [2.2] 14 [2.1] 7 [2.4]
Prostate (49) (50) (49) (50)
Inflammation, Chronic 2 [2.5]
Seminal Vesicle (50) (50) (50) (50)
Atrophy 1 [2.0]
Testes (50) (50) (50) (50)
Germinal Epithelium, Atrophy 1 [2.0] 4 [2.0] 8 [2.3] 14 [2.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hyperplasia 4 [3.0] 10 [2.8] 20 [2.1] 42 [2.5]
Lymph Node (2) (3) (1)
Bronchial, Hyperplasia, Lymphoid 1 [2.0]
Lymph Node, Mandibular (48) (46) (45) (50)
Atrophy 1 [3.0] 2 [2.0] 4 [2.8]
Ectasia 1 [2.0]
Hyperplasia, Lymphoid 10 [2.1] 14 [2.3] 9 [2.6] 13 [2.2]
Pigmentation 8 [2.1] 6 [2.2] 9 [2.0] 6 [2.0]
Lymph Node, Mesenteric (47) (47) (46) (48)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 10
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Angiectasis 1 [3.0]
Atrophy 1 [2.0] 1 [3.0] 2 [2.5] 2 [3.0]
Hemorrhage 4 [1.8] 2 [1.5] 2 [2.0]
Hyperplasia, Lymphoid 7 [2.4] 7 [2.1] 15 [2.4] 10 [2.3]
Necrosis 1 [4.0] 1 [3.0]
Spleen (50) (50) (49) (50)
Angiectasis 1 [2.0]
Atrophy 1 [3.0] 4 [3.0] 3 [2.7]
Hematopoietic Cell Proliferation 10 [2.2] 21 [2.3] 38 [2.5] 45 [2.9]
Pigmentation 1 [2.0] 16 [1.1] 33 [1.6] 43 [2.2]
Lymphoid Follicle, Atrophy 4 [3.3] 14 [1.6] 30 [1.8]
Lymphoid Follicle, Hyperplasia 5 [2.0] 2 [1.5] 2 [2.0]
Thymus (47) (46) (46) (47)
Atrophy 7 [2.6] 5 [2.2] 9 [3.4] 8 [3.1]
Cyst 1 [3.0] 1 [3.0] 1 [3.0]
Hyperplasia, Lymphoid 1 [3.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Inflammation, Chronic 1 [4.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (2)
Atrophy 1 [2.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression 1 [3.0]
Peripheral Nerve (1) (1)
Atrophy 1 [2.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Edema 1 [2.0] 3 [2.0] 1 [2.0] 3 [2.0]
Hemorrhage 4 [2.0] 8 [1.5] 4 [1.8] 2 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 11
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 08/06/04
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 09:44:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Hyperplasia, Lymphoid 1 [2.0] 2 [2.0] 2 [2.0] 4 [2.0]
Infiltration Cellular, Histiocyte 4 [2.8] 4 [3.0] 4 [2.0] 2 [3.0]
Inflammation, Chronic 1 [1.0] 2 [1.5]
Metaplasia, Osseous 2 [1.0]
Thrombosis 1 [1.0] 1 [2.0]
Alveolar Epithelium, Hyperplasia 5 [3.2] 3 [2.0] 1 [1.0] 3 [2.3]
Alveolar Epithelium, Hyperplasia, Multifocal 1 [3.0]
Nose (50) (50) (50) (50)
Foreign Body 1 3 3 2
Inflammation, Chronic 1 [1.0] 4 [2.5] 3 [1.7] 2 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (50)
Cataract 1 [3.0] 1 [2.0]
Inflammation, Chronic 1 [3.0] 2 [3.0] 2 [2.0] 2 [3.0]
Cornea, Hyperplasia 1 [2.0] 1 [2.0]
Harderian Gland (50) (50) (48) (50)
Hyperplasia, Focal 1 [2.0] 2 [2.5]
Inflammation, Chronic 3 [1.7] 4 [1.8] 2 [2.0]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Cyst 13 [3.0] 11 [3.0] 12 [3.0] 19 [3.0]
Hydronephrosis 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0] 3 [2.0] 3 [2.0] 3 [2.0]
Infarct 6 [1.8] 6 [1.8] 6 [2.2] 1 [2.0]
Inflammation, Suppurative 1 [4.0]
Metaplasia, Osseous 5 [1.8] 3 [1.3] 2 [1.0] 3 [1.7]
Nephropathy 34 [1.2] 43 [1.5] 32 [1.5] 31 [1.1]
Papilla, Necrosis 1 [2.0]
Renal Tubule, Hyperplasia 1 [1.0] 1 [1.0] 2 [1.0] 3 [1.7]
Renal Tubule, Pigmentation 1 [2.0] 2 [1.5] 45 [2.5]
Urethra (1)
Angiectasis 1 [4.0]
Inflammation, Suppurative 1 [3.0]
Urinary Bladder (50) (50) (50) (50)
Transitional Epithelium, Hyperplasia 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------